10 Undervalued Stocks to Invest in According to Goldman Sachs

6. AbbVie Inc. (NYSE:ABBV)

Forward Price-to-Earnings Multiple: 15.27x

Number of Hedge Fund Holders: 93

AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in.

On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug licensed from Danish biotech Gubra. Emphasizing differentiation rather than a first-mover strategy, the company’s management highlighted that existing first-generation GLP-1 therapies pose problems related to tolerability and durability. These shortcomings drive high patient drop-off rates, management noted.

In contrast to GLP-1 drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound, amylin-based therapies aim to replicate a pancreas-derived hormone that reduces appetite and slows gastric emptying. Furthermore, initial studies show that these drugs help preserve muscle mass while promoting weight loss. Thus, AbbVie Inc. (NYSE:ABBV) believes patients may be more likely to stay on treatment longer. Management appears optimistic about capitalizing on the market, projected to generate roughly $150 billion in annual sales over the next decade.

AbbVie Inc. (NYSE:ABBV) also aims to leverage the overlap between cosmetic and weight-loss patients on the back of its established aesthetics franchise. With this, the company could integrate care models for more efficient customer engagement.

AbbVie Inc. (NYSE:ABBV), a research-based biopharmaceutical company, develops therapies across immunology, oncology, neuroscience, virology, aesthetics, and metabolic diseases. The company leverages diversified pipelines and global commercialization capabilities, driving durable growth and innovation.